Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors a pilot study of the value of serology to determine population exposure
Background. The extent of spread of SARS coronavirus 2 (SARS CoV 2) in the UK and elsewhere is unknown because typically only symptomatic individuals are diagnosed. We performed a serological study of recent blood donors in Scotland to detect antibodies to SARS CoV 2 as a marker of past infection. Methods. A pseudotyped SARS CoV 2 virus microneutralisation assay was used to detect neutralising antibodies to SARS CoV 2. The study group comprised samples from 1000 blood donors collected in Scotland during March, 2020. Controls were collected from 100 donors in Scotland during 2019. Findings. All samples collected on the 17th March, 2020 (n=500) were negative in the pseudotyped SARS CoV 2 virus microneutralisation assay. Neutralising antibodies were detected in 5 of the 500 samples collected 21st to 23rd March; one further sample was reactive in an anti spike ELISA. Interpretation. Although we cannot use the rise in numbers seropositive to infer the contemporary seroprevalence or the growth rate of the epidemic, we note that they are consistent with frequency of reported diagnosed infections and SARS CoV 2 associated deaths reported in that time period in Scotland, given that seroconversion takes up to 2 3 weeks. It should also be noted that blood donors are not representative of the general population; in particular, those with a history of recent respiratory infections are deferred. Finally, it is unknown what proportion of infected individuals seroconvert and become reactive in the assays used. Serial follow up studies are needed to track infection and seroconversion in this and other similar populations However, these data indicate that sero surveys of blood banks can serve as a useful tool for tracking the emergence and progression of an epidemic like the current SARS CoV 2 outbreak.
medRxiv